Puma Biotechnology, the new start-up of the founder of Cougar Biotechnology, has in-licensed worldwide development and commercialisation rights to Pfizer’s investigational pan-HER inhibitor neratinib following a pipeline review at the big pharma company. The drug is currently being studied in Phase II and Phase III trials in patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer and Puma has raised approximately US$55 M in a private placement to help fund its further development.